Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tri-specific killer engager cell therapy - Ingenium Therapeutics

Next Previous
X
Search
Drug Profile

Tri-specific killer engager cell therapy - Ingenium Therapeutics

Alternative Names: TANK-E; TriKE TANK-E

Latest Information Update: 23 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ingenium Therapeutics
  • Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 29 Jul 2024 Ingenium Therapeutics has patents pending for 'Composition for enhancing activity of natural killer cells' in Australia
  • 29 Jul 2024 Preclinical trials in Solid tumours in South Korea (Parenteral) prior to July 2024 (Ingenium Therapeutics pipeline, July 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top